Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Approximately 50% of patients with melanoma harbor a BRAF mutation and are eligible for targeted therapy with BRAF/MEK inhibitors (BRAFi/MEKi). Despite a response rate of nearly 70%, more than half of the patients will experience disease progression within a year due to tumor resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Priantti, Jonathan N., Vilbert, Maysa, Madeira, Thiago, Moraes, Francisco Cezar A., Hein, Erica C. Koch, Saeed, Anwaar, Cavalcante, Ludimila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417341/
https://www.ncbi.nlm.nih.gov/pubmed/37568570
http://dx.doi.org/10.3390/cancers15153754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417341/
https://www.ncbi.nlm.nih.gov/pubmed/37568570
http://dx.doi.org/10.3390/cancers15153754

Ejemplares similares